Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

CUECue Biopharma, Inc.

Nasdaq · CIK 0001645460
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts277

Identity from submissions API

NameCue Biopharma, Inc.
CIK0001645460
TickersCUE
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN473324577
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone617-949-2680
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Imagen Biopharma, Inc. (2015-06-19T04:00:00.000Z → 2015-06-19T04:00:00.000Z)
Business address
100 CHESTNUT STREET
SUITE 300
SOMERVILLE
MA
02143
MA
Mailing address
100 CHESTNUT STREET
SUITE 300
SOMERVILLE
MA
02143
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

558 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 10-Q 10-Q 0001193125-26-463755 001-38327 261562456 34 14813162 1 1
2026-11-16 8-K 8-K 2.02,9.01 0001193125-26-463741 001-38327 261562365 34 477636 1 1
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005293 005-90232 261559142 34 11511
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000938206-26-000052 005-90232 261556310 34 7368
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005042 005-90232 261555061 34 14893
2026-11-10 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001420506-26-002561 005-90232 261541337 34 11074
2026-10-14 4 xslF345X06/form4-10152026_011030.xml 0001579629-26-000012 5381
2026-10-14 4 xslF345X06/form4-10152026_011010.xml 0002138368-26-000009 5381
2026-10-14 4 xslF345X06/form4-10152026_011031.xml 0001725092-26-000019 6872
2026-10-13 144 xsl144X01/primary_doc.xml 0001725092-26-000017 001-38327 261458107 33 6566
2026-10-13 144 xsl144X01/primary_doc.xml 0001579629-26-000010 001-38327 261458102 33 5878
2026-10-08 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-107721 005-90232 261448316 34 32327
2026-09-21 8-K 8-K 7.01,8.01,9.01 0001193125-26-396094 001-38327 261392307 34 10521230 1 1
2026-08-28 4/A xslF345X06/form4a-08282026_090818.xml 0002059447-26-000006 5656
2026-08-28 4/A xslF345X06/form4a-08282026_090821.xml 0001974756-26-000006 5660
2026-08-21 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001725092-26-000015 005-90232 261305477 34 15062
2026-08-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002724 333-298266 261301601 33 1787
2026-08-18 CORRESP filename1.htm 0001193125-26-355392 8263
2026-08-17 4 xslF345X06/form4-08172026_100832.xml 0001579629-26-000008 13799
2026-08-17 4 xslF345X06/form4-08172026_100852.xml 0002138368-26-000007 13796
2026-08-17 UPLOAD filename1.pdf 0000000000-26-008092 333-298266 146483
2026-08-14 4 xslF345X06/form4-08152026_120800.xml 0001725092-26-000013 18551
2026-08-14 144 xsl144X01/primary_doc.xml 0001725092-26-000011 001-38327 261284438 33 5692
2026-08-14 10-Q 10-Q 0001193125-26-352128 001-38327 261280892 34 11426664 1 1
2026-08-14 8-K 8-K 2.02 0001193125-26-352126 001-38327 261280847 34 413409 1 1
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000938206-26-000041 005-90232 261276099 34 7449
2026-08-13 144 xsl144X01/primary_doc.xml 0001579629-26-000006 001-38327 261275736 33 5003
2026-08-12 S-3 S-3 0001193125-26-346867 333-298266 261267611 33 384812 1 1
2026-08-03 8-K 8-K 5.02 0001193125-26-330730 001-38327 261233841 34 147195 1 1
2026-08-03 4 xslF345X06/form4-08032026_080815.xml 0001320383-26-000006 7441
2026-08-03 3 xslF345X06/form3-08032026_080851.xml 0001320383-26-000004 16500
2026-07-30 4/A xslF345X06/form4a-07302026_080752.xml 0001725092-26-000009 9393
2026-07-22 D xslFormDX01/primary_doc.xml 06b 0001645460-26-000004 021-591745 261192975 33 11349
2026-07-15 4 xslF345X06/form4-07152026_100742.xml 0002008790-26-000006 7504
2026-07-15 3 xslF345X06/form3-07152026_100719.xml 0002008790-26-000004 16337
2026-07-10 4 xslF345X06/form4-07102026_110755.xml 0001974756-26-000004 5075
2026-07-10 4 xslF345X06/form4-07102026_110706.xml 0001820365-26-000009 5078
2026-07-10 4 xslF345X06/form4-07102026_110706.xml 0002059447-26-000004 5276
2026-07-10 4 xslF345X06/form4-07102026_110702.xml 0002137444-26-000007 5081
2026-07-10 4 xslF345X06/form4-07102026_110720.xml 0002138368-26-000005 7823
2026-07-10 4 xslF345X06/form4-07102026_110713.xml 0001579629-26-000004 7823
2026-07-10 4 xslF345X06/form4-07102026_110711.xml 0001725092-26-000006 7806
2026-07-10 8-K 8-K 1.01,3.02,5.02,8.01,9.01 0001193125-26-301052 001-38327 261169512 34 587017 1 1
2026-07-01 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002180 333-296896 261147581 33 1787
2026-06-29 CORRESP filename1.htm 0001193125-26-288417 8371
2026-06-25 UPLOAD filename1.pdf 0000000000-26-006372 333-296896 145566
2026-06-18 S-3 S-3 0001193125-26-275808 333-296896 261102523 33 434031 1 1
2026-06-17 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002046 333-296456 261100279 33 1787
2026-06-15 CORRESP filename1.htm 0001193125-26-271175 8073
2026-06-11 3 xslF345X06/form3-06112026_090651.xml 0002138368-26-000003 3289
2026-06-11 3 xslF345X06/form3-06112026_090627.xml 0001579629-26-000002 5240
2026-06-10 UPLOAD filename1.pdf 0000000000-26-005827 333-296456 145800
2026-06-08 4 xslF345X06/form4-06082026_080603.xml 0001820365-26-000006 5615
2026-06-08 3 xslF345X06/form3-06082026_080650.xml 0001820365-26-000004 3263
2026-06-03 4 xslF345X06/form4-06032026_090611.xml 0001725092-26-000004 8829
2026-06-03 8-K 8-K 5.02,5.07,9.01 0001193125-26-255479 001-38327 261060860 34 209304 1 1
2026-06-03 S-8 S-8 0001193125-26-255427 333-296458 261060652 33 196984 1 1
2026-06-03 S-3 S-3 0001193125-26-255418 333-296456 261060614 33 602839
2026-06-02 4 xslF345X06/form4-06032026_120657.xml 0002137444-26-000005 5619
2026-06-02 3 xslF345X06/form3-06032026_120656.xml 0002137444-26-000004 16365
2026-06-02 8-K 8-K 5.02,8.01 0001193125-26-253709 001-38327 261056983 34 151348 1 1
2026-05-21 DEF 14A DEF 14A 0001193125-26-233369 001-38327 261006064 34 980513
2026-05-14 8-K 8-K 9.01 0001193125-26-224101 001-38327 26979276 34 364274 1 1
2026-05-14 10-Q 10-Q 0001193125-26-224091 001-38327 26979253 34 8380673 1 1
2026-05-14 D xslFormDX01/primary_doc.xml 06b 0001645460-26-000003 021-584091 26978965 33 13254
2026-05-11 PRE 14A PRE 14A 0001193125-26-217130 001-38327 26965977 34 819997
2026-05-07 3 3 0001193125-26-211809 3116
2026-05-07 4 4 0001193125-26-211806 6815
2026-05-01 S-8 S-8 0001193125-26-198622 333-295482 26928440 33 273747 1 1
2026-05-01 8-K 8-K 1.01,3.02,5.02,8.01,9.01 0001193125-26-198588 001-38327 26928388 34 1368820 1 1
2026-04-22 8-K 8-K 3.03,5.03 0001193125-26-168907 001-38327 26881471 34 252731 1 1
2026-04-13 8-K 8-K 5.07 0001193125-26-152826 001-38327 26857772 34 227909 1 1
2026-04-10 4 4 0001193125-26-151202 5453
2026-04-10 4 4 0001193125-26-151201 5486
2026-04-10 4 4 0001193125-26-151200 5530
2026-04-07 8-K 8-K 8.01 0001193125-26-144569 001-38327 26842950 34 198976 1 1
2026-03-31 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001020 333-294366 26824502 33 1786
2026-03-27 CORRESP filename1.htm 0001193125-26-129018 5927
2026-03-27 DEFA14A DEFA14A 0001193125-26-129007 001-38327 26807335 34 30438
2026-03-27 8-K 8-K 5.02 0001193125-26-128993 001-38327 26807248 34 145722 1 1
2026-03-23 UPLOAD filename1.pdf 0000000000-26-002905 333-294366 40086
2026-03-16 S-3 S-3 0001193125-26-108656 333-294366 26759949 33 1476422 1 1
2026-03-16 ARS ARS 0001193125-26-108307 001-38327 26756503 34 3728099
2026-03-16 DEF 14A DEF 14A 0001193125-26-108301 001-38327 26756497 34 4762981 1 1
2026-03-16 8-K 8-K 2.02,9.01 0001193125-26-108292 001-38327 26756473 34 443531 1 1
2026-03-16 10-K 10-K 0001193125-26-108287 001-38327 26756468 34 15815970 1 1
2026-03-06 PRE 14A PRE 14A 0001193125-26-096441 001-38327 26730727 34 4812713 1 1
2026-02-18 8-K 8-K 8.01 0001193125-26-056983 001-38327 26648050 34 199529 1 1
2026-02-12 8-K 8-K 5.02 0001193125-26-047717 001-38327 26623489 34 199388 1 1
2026-01-06 4 4 0001193125-26-004359 5354
2026-01-06 4 4 0001193125-26-004358 5523
2026-01-06 4 4 0001193125-26-004356 5391
2026-01-06 4 4 0001193125-26-004357 5348
2026-01-06 4 4 0001193125-26-004355 5397
2026-01-06 4 4 0001193125-26-004354 5385
2026-01-02 4 4 0001193125-26-000900 9890
2025-12-29 144 xsl144X01/primary_doc.xml 0001950047-25-010720 001-38327 251609050 33 4690
2025-12-19 8-K 8-K 1.01,8.01,9.01 0001193125-25-326925 001-38327 251587859 34 651973 1 1
2025-12-19 424B5 424B5 0001193125-25-326847 333-271786 251587636 33 605937
2025-12-18 424B5 424B5 0001193125-25-324820 333-271786 251583173 33 608055
2025-12-05 4 4 0001193125-25-310067 7760
2025-11-25 4 4 0001193125-25-296986 5247
2025-11-25 4 4 0001193125-25-296985 5288
2025-11-24 8-K 8-K 7.01 0001193125-25-292093 001-38327 251509636 34 15459987 1 1
2025-11-20 8-K 8-K 5.02 0001193125-25-289713 001-38327 251502921 34 196215 1 1
2025-11-12 10-Q 10-Q 0001193125-25-277466 001-38327 251472387 34 9065284 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001193125-25-277468 001-38327 251472373 34 407599 1 1
2025-11-06 8-K 8-K 1.01,7.01,9.01 0001193125-25-268135 001-38327 251456267 34 306079 1 1
2025-10-02 4 4 0001193125-25-228920 5285
2025-10-02 3 3 0001193125-25-228919 21331
2025-09-29 8-K 8-K 5.02 0000950130-25-000140 001-38327 251355976 34 220321 1 1
2025-08-12 S-8 S-8 0000950170-25-107323 333-289528 251206816 33 370204 1 1
2025-08-12 10-Q 10-Q 0000950170-25-107270 001-38327 251206471 34 8332355 1 1
2025-08-12 8-K 8-K 2.02,9.01 0000950170-25-107268 001-38327 251206460 34 544467 1 1
2025-07-01 8-K 8-K 1.01 0000950170-25-092168 001-38327 251096171 34 199104 1 1
2025-06-10 8-K 8-K 5.02,5.03,5.07,9.01 0000950170-25-084279 001-38327 251036993 34 504868 1 1
2025-06-06 4 4 0000950170-25-083026 5681
2025-06-06 3 3 0000950170-25-083025 12370
2025-05-27 DEFA14A DEFA14A 0000950170-25-077389 001-38327 25984307 34 106655
2025-05-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-044863 005-90232 25958891 34 21607
2025-05-12 10-Q 10-Q 0000950170-25-069125 001-38327 25934565 34 7928619 1 1
2025-05-12 8-K 8-K 2.02,9.01 0000950170-25-069124 001-38327 25934560 34 512293 1 1
2025-04-25 ARS ARS 0000950170-25-058683 001-38327 25873613 34 18948254
2025-04-25 DEF 14A DEF 14A 0000950170-25-058681 001-38327 25873611 34 4090615 1 1
2025-04-25 DEFA14A DEFA14A 0000950170-25-058677 001-38327 25873605 34 1040634
2025-04-15 8-K 8-K 1.01,2.02,8.01,9.01 0001193125-25-081592 001-38327 25840186 34 650376 1 1
2025-04-15 424B5 424B5 0001193125-25-081566 333-271786 25840147 33 585359
2025-04-14 424B5 424B5 0001193125-25-080293 333-271786 25836791 33 586882
2025-04-14 8-K 8-K 1.01 0001193125-25-080277 001-38327 25836651 34 146653 1 1
2025-04-14 PRE 14A PRE 14A 0000950170-25-053694 001-38327 25835983 34 8518633 1 1
2025-03-31 S-8 S-8 0000950170-25-047705 333-286258 25793263 33 237419
2025-03-31 8-K 8-K 2.02,9.01 0000950170-25-047678 001-38327 25792979 34 402024 1 1
2025-03-31 10-K 10-K 0000950170-25-047677 001-38327 25792967 34 16385650 1 1
2025-03-25 4 4 0000950170-25-044348 5277
2025-03-25 4 4 0000950170-25-044347 5274
2025-03-25 4 4 0000950170-25-044346 5310
2025-03-25 4 4 0000950170-25-044345 5236
2025-03-25 4 4 0000950170-25-044344 5307
2025-03-25 4 4 0000950170-25-044343 5312
2025-03-21 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001420506-25-000687 005-90232 25761937 34 15898
2025-03-12 8-K 8-K 5.02 0000950170-25-037885 001-38327 25731623 34 199245 1 1
2025-03-12 4 4 0000950170-25-037889 5551
2025-03-12 3 3 0000950170-25-037879 12176
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-001077 005-90232 25630535 34 11464
2025-01-03 4 4 0000950170-25-001103 5546
2025-01-03 4 4 0000950170-25-001101 5540
2025-01-03 4 4 0000950170-25-001107 5497
2025-01-03 4 4 0000950170-25-001106 5427
2025-01-03 4 4 0000950170-25-001105 5501
2024-12-18 4 4 0000950170-24-137860 4992
2024-12-16 UPLOAD filename1.pdf 0000000000-24-013826 001-38327 39566
2024-12-11 CORRESP filename1.htm 0001193125-24-275538 29676
2024-12-05 UPLOAD filename1.pdf 0000000000-24-013392 001-38327 43293
2024-11-29 4 4 0000950170-24-131890 5476
2024-11-29 3 3 0000950170-24-131889 11970
2024-11-14 10-Q 10-Q 0000950170-24-127005 001-38327 241461415 34 7635393 1 1
2024-11-14 8-K 8-K 2.02 0000950170-24-127004 001-38327 241461381 34 345207 1 1
2024-10-08 8-K 8-K 5.03,5.07,9.01 0000950170-24-113520 001-38327 241360306 34 220016 1 1
2024-10-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001781002-24-000050 005-90232 241358561 34 10973
2024-10-04 8-K 8-K 1.01,9.01 0000950170-24-112887 001-38327 241354844 34 245772 1 1
2024-09-27 8-K 8-K 1.01,8.01,9.01 0001193125-24-227977 001-38327 241335092 34 643306 1 1
2024-09-27 424B5 424B5 0001193125-24-227947 333-271786 241334876 33 598061
2024-09-26 424B5 424B5 0001193125-24-226974 333-271786 241329419 33 614858
2024-09-10 DEF 14A DEF 14A 0000950170-24-105104 001-38327 241290022 34 673540
2024-09-05 3 3 0000950170-24-103956 11840
2024-09-05 4 4 0000950170-24-103955 5309
2024-09-03 8-K 8-K 5.02 0000950170-24-102851 001-38327 241274501 34 192042 1 1
2024-08-28 PRE 14A PRE 14A 0000950170-24-101373 001-38327 241255226 34 666671
2024-08-16 8-K 8-K 3.01 0000950170-24-098032 001-38327 241216586 34 193052 1 1
2024-08-14 10-Q 10-Q 0000950170-24-096967 001-38327 241207185 34 7644336 1 1
2024-07-25 8-K 8-K 5.02,8.01,9.01 0000950170-24-086476 001-38327 241141947 34 274325 1 1
2024-06-07 8-K 8-K 5.02,5.07 0000950170-24-070566 001-38327 241029132 34 219306 1 1
2024-06-07 4 4 0000950170-24-070565 5318
2024-06-07 4 4 0000950170-24-070564 5259
2024-06-07 4 4 0000950170-24-070563 5569
2024-06-07 4 4 0000950170-24-070562 5239
2024-06-07 3 3 0000950170-24-070561 14159
2024-06-07 4 4 0000950170-24-070559 5280
2024-05-24 DEFA14A DEFA14A 0000950170-24-064528 001-38327 24984085 34 262447
2024-05-09 8-K 8-K 2.02,9.01 0000950170-24-056848 001-38327 24930309 34 332092 1 1
2024-05-09 10-Q 10-Q 0000950170-24-056838 001-38327 24930271 34 7586712 1 1
2024-04-26 DEF 14A DEF 14A 0000950170-24-049072 001-38327 24883427 34 1438185
2024-04-26 DEFA14A DEFA14A 0000950170-24-049044 001-38327 24883227 34 289707
2024-04-26 ARS ARS 0000950170-24-049039 001-38327 24883206 34 31930025
2024-03-28 S-8 S-8 0000950170-24-038084 333-278329 24799548 33 146771
2024-03-28 10-K 10-K 0000950170-24-038059 001-38327 24799154 34 12294132 1 1
2024-03-11 SC 13G CUEBIOPHARMA13G 0001781002-24-000025 005-90232 24739631 34 41268
2024-03-08 4 4 0000950170-24-028613 5242
2024-03-08 4 4 0000950170-24-028611 5259
2024-03-08 4 4 0000950170-24-028612 5283
2024-03-08 4 4 0000950170-24-028609 5280
2024-03-08 4 4 0000950170-24-028608 5318
2024-02-22 4 4 0000950170-24-018724 5495
2024-02-07 SC 13G us22978p1066_020724.txt 0001086364-24-006803 005-90232 24605674 34 12461
2024-01-31 SC 13G us22978p1066_013124.txt 0001086364-24-006036 005-90232 24582172 34 13323
2024-01-04 4 4 0000950170-24-001833 5460
2024-01-04 4 4 0000950170-24-001830 5421
2024-01-04 4 4 0000950170-24-001829 5347
2024-01-04 4 4 0000950170-24-001828 5466
2024-01-04 4 4 0000950170-24-001827 5417
2023-11-03 10-Q 10-Q 0000950170-23-058838 001-38327 231376523 34 8708703 1 1
2023-09-14 8-K 8-K 5.02 0001193125-23-235298 001-38327 231255125 34 139029 1 1
2023-08-29 4 FORM 4 SUBMISSION 0001209191-23-047575 4552
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046000 4574
2023-08-08 10-Q 10-Q 0000950170-23-039770 001-38327 231151137 34 9848637 1 1
2023-07-25 4 FORM 4 SUBMISSION 0001209191-23-043278 5411
2023-07-25 4 FORM 4 SUBMISSION 0001209191-23-043277 5378
2023-07-25 4 FORM 4 SUBMISSION 0001209191-23-043276 5377
2023-07-25 4 FORM 4 SUBMISSION 0001209191-23-043274 5335
2023-07-25 4 FORM 4 SUBMISSION 0001209191-23-043273 5355
2023-06-09 8-K 8-K 5.07 0001193125-23-164491 001-38327 231005811 34 160808 1 1
2023-05-26 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-05-26 16:30:00 9999999995-23-001552 333-271786 23971253 33 1744
2023-05-24 CORRESP filename1.htm 0001193125-23-152982 6173
2023-05-16 UPLOAD filename1.pdf 0000000000-23-005199 40198
2023-05-09 S-3 S-3 0001193125-23-139563 333-271786 23903509 33 1400402
2023-05-09 10-Q 10-Q 0000950170-23-019646 001-38327 23902022 34 8980925 1 1
2023-04-28 ARS ARS 0001193125-23-126930 001-38327 23866144 34 21165047
2023-04-28 DEFA14A DEFA14A 0001193125-23-126907 001-38327 23866049 34 350265
2023-04-28 DEF 14A DEF 14A 0001193125-23-126883 001-38327 23865910 34 1779194
2023-04-25 3 FORM 3 SUBMISSION 0001209191-23-025525 7476
2023-04-25 8-K 8-K 5.02 0000950170-23-014246 001-38327 23841787 34 213429 1 1
2023-04-21 4 FORM 4 SUBMISSION 0001209191-23-025142 5380
2023-04-13 3 FORM 3 SUBMISSION 0001209191-23-024221 8086
2023-04-13 4 FORM 4 SUBMISSION 0001209191-23-024220 5424
2023-04-12 8-K 8-K 5.02 0000950170-23-012492 001-38327 23814680 34 261433 1 1
2023-03-27 4 FORM 4 SUBMISSION 0001209191-23-021201 9108
2023-03-21 S-8 S-8 0000950170-23-008929 333-270718 23749727 33 211084
2023-03-21 10-K 10-K 0000950170-23-008927 001-38327 23749714 34 13582046 1 1
2023-03-10 8-K 8-K 5.02 0000950170-23-007304 001-38327 23724054 34 211560 1 1
2023-02-21 4 FORM 4 SUBMISSION 0001209191-23-011270 5389
2023-02-21 4 FORM 4 SUBMISSION 0001209191-23-011255 5314
2023-02-21 4 FORM 4 SUBMISSION 0001209191-23-011249 5297
2023-02-21 4 FORM 4 SUBMISSION 0001209191-23-011247 5336
2023-02-21 4 FORM 4 SUBMISSION 0001209191-23-011245 5337
2023-02-14 SC 13G CUE BIOPHARMA, INC. 0000902664-23-001667 005-90232 23623438 34 73770
2023-02-03 SC 13G/A Cue_Biopharma_Inc.txt 0000093751-23-000136 005-90232 23584455 34 8257
2023-01-19 4 FORM 4 SUBMISSION 0001209191-23-003988 5372
2023-01-19 3 FORM 3 SUBMISSION 0001209191-23-003987 7093
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-001796 5474
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-001789 5478
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-001785 5386
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-001780 5490
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-001776 5399
2022-12-30 424B7 424B7 0001193125-22-315454 333-268687 221502336 33 255019
2022-12-15 424B3 424B3 0001193125-22-305962 333-268687 221465360 33 425993
2022-12-14 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-12-14 16:00:00 9999999995-22-003541 333-268687 221463568 33 1745
2022-12-12 CORRESP filename1.htm 0001193125-22-302735 5122
2022-12-09 UPLOAD filename1.pdf 0000000000-22-013274 40172
2022-12-06 S-3 S-3 0001193125-22-299361 333-268687 221447655 33 562986
2022-12-02 SC 13G/A SC 13G/A 0001104659-22-124192 005-90232 221443074 34 47826
2022-11-21 D xslFormDX01/primary_doc.xml 06b 0001645460-22-000005 021-465492 221405847 33 15423
2022-11-18 SC 13G sc13g13606cue_11182022.htm 0000921895-22-003095 005-90232 221401937 34 146291
2022-11-15 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-22-285792 001-38327 221391585 34 937494 1 1
2022-11-14 10-Q 10-Q 0000950170-22-024991 001-38327 221385337 34 9846530 1 1
2022-08-23 4 FORM 4 SUBMISSION 0001209191-22-047161 8784
2022-08-04 10-Q 10-Q 0000950170-22-014747 001-38327 221136667 34 8968407 1 1
2022-07-08 SC 13G us22978p1066_070822.txt 0000834237-22-010285 005-90232 221075041 34 12263
2022-06-22 8-K 8-K 5.02 0001193125-22-178755 001-38327 221031993 34 143681 1 1
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037394 8626
2022-06-10 8-K 8-K 5.07 0001193125-22-171921 001-38327 221008794 34 189509 1 1
2022-05-31 4 FORM 4 SUBMISSION 0001209191-22-032800 4465
2022-05-25 4 FORM 4 SUBMISSION 0001209191-22-031791 9047
2022-05-10 10-Q 10-Q 0000950170-22-008990 001-38327 22909921 34 7750429 1 1
2022-04-29 DEFA14A DEFA14A 0001193125-22-133541 001-38327 22875127 34 408304
2022-04-29 DEF 14A DEF 14A 0001193125-22-133519 001-38327 22875032 34 1599435
2022-04-04 4 FORM 4 SUBMISSION 0001209191-22-022578 8705
2022-04-04 4 FORM 4 SUBMISSION 0001209191-22-022570 10296
2022-04-04 4 FORM 4 SUBMISSION 0001209191-22-022568 6285
2022-03-30 8-K 8-K 1.01,2.03,9.01 0001193125-22-089787 001-38327 22786546 34 442690 1 1
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021502 5404
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021458 7688
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021456 7633
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021454 5373
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021449 5380
2022-03-29 4 FORM 4 SUBMISSION 0001209191-22-021446 7673
2022-03-16 S-8 S-8 0001193125-22-077352 333-263624 22745805 33 59752
2022-03-16 10-K 10-K 0000950170-22-003969 001-38327 22745804 34 11504396 1 1
2022-02-18 8-K 8-K 1.01,2.03 0001193125-22-046662 001-38327 22653275 34 149884 1 1
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-022907 005-90232 22632621 34 88986
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-021636 005-90232 22625426 34 59421
2022-02-10 SC 13G CUE_BIOPHARMA_INC.txt 0000093751-22-000136 005-90232 22612991 34 8474
2022-02-03 SC 13G/A us22978p1066_020322.txt 0000834237-22-006474 005-90232 22589232 34 13333
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001069 5517
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001052 5526
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001051 5479
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001050 5389
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001046 5402
2022-01-05 4 FORM 4 SUBMISSION 0000899243-22-001045 5479
2022-01-04 4 FORM 4 SUBMISSION 0000899243-22-000537 5403
2022-01-04 3 FORM 3 SUBMISSION 0000899243-22-000530 7539
2021-12-21 4 FORM 4 SUBMISSION 0000899243-21-049172 5367
2021-11-17 4 FORM 4 SUBMISSION 0000899243-21-045070 15137
2021-11-17 4 FORM 4 SUBMISSION 0000899243-21-045069 9256
2021-11-15 4 FORM 4 SUBMISSION 0000899243-21-044603 9263
2021-11-15 8-K 8-K 7.01,9.01 0001193125-21-328969 001-38327 211406410 34 12019104 1 1
2021-11-09 10-Q 10-Q 0001564590-21-055766 001-38327 211392716 34 7589230 1 1
2021-10-08 4 FORM 4 SUBMISSION 0001209191-21-060022 8778
2021-10-08 4 FORM 4 SUBMISSION 0001209191-21-060021 8780
2021-10-05 4 FORM 4 SUBMISSION 0001209191-21-059698 14995
2021-10-01 424B5 424B5 0001193125-21-289860 333-239357 211299883 33 324979
2021-10-01 8-K 8-K 1.01,8.01,9.01 0001193125-21-289829 001-38327 211299756 34 418789 1 1
2021-10-01 424B5 424B5 0001193125-21-289821 333-239357 211299703 33 10218
2021-09-27 4 FORM 4 SUBMISSION 0001209191-21-057785 9263
2021-09-27 4 FORM 4 SUBMISSION 0001209191-21-057784 5155
2021-08-09 10-Q 10-Q 0001564590-21-042619 001-38327 211156466 34 6989204 1 1
2021-06-14 8-K 8-K 5.07 0001564590-21-032772 001-38327 211014552 34 211436 1 1
2021-05-21 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-21-074981,2021-05-21 9999999995-21-002052 333-239357 21950955 33 1761
2021-05-21 POS AM POS AM 0001193125-21-169269 333-239357 21949082 33 441122
2021-05-10 10-Q 10-Q 0001564590-21-026048 001-38327 21907218 34 6193319 1 1
2021-04-26 DEFA14A DEFA14A 0001564590-21-020527 001-38327 21853825 34 251160
2021-04-26 DEF 14A DEF 14A 0001564590-21-020525 001-38327 21853740 34 2095275
2021-03-18 8-K 8-K 7.01,9.01 0001193125-21-084993 001-38327 21753132 34 12235021 1 1
2021-03-17 4 FORM 4 SUBMISSION 0001209191-21-021293 15257
2021-03-09 S-8 S-8 0001193125-21-074995 333-254045 21726758 33 51951
2021-03-09 POS AM POS AM 0001193125-21-074981 333-239357 21726665 33 438247
2021-03-09 10-K 10-K 0001564590-21-011777 001-38327 21726495 34 16182428 1 1
2021-03-09 POSASR POSASR 0001193125-21-074863 333-239357 21725762 33 450323
2021-02-18 4 FORM 4 SUBMISSION 0000899243-21-007232 19179
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007230 9799
2021-02-16 SC 13G SC 13G 0001193125-21-043231 005-90232 21632120 34 83189
2021-02-12 4 FORM 4 SUBMISSION 0000899243-21-006362 5368
2021-02-12 4 FORM 4 SUBMISSION 0000899243-21-006360 5324
2021-02-12 4 FORM 4 SUBMISSION 0000899243-21-006358 5352
2021-02-12 4 FORM 4 SUBMISSION 0000899243-21-006355 5314
2021-02-12 4 FORM 4 SUBMISSION 0000899243-21-006354 5327
2021-02-12 SC 13G/A SC 13G/A 0001104659-21-021772 005-90232 21626310 34 49611
2021-02-12 SC 13G/A CUE BIOPHARMA, INC. 0000902664-21-001246 005-90232 21622931 34 58312
2021-02-01 5 FORM 5 SUBMISSION 0000899243-21-003885 9739
2021-01-29 SC 13G/A us22978p1066_012921.txt 0000834237-21-003903 005-90232 21568742 34 13285
2021-01-22 4 FORM 4 SUBMISSION 0000899243-21-002947 5148
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000712 5527
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000711 5525
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000710 5406
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000705 5478
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000702 5516
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000701 5478
2021-01-06 4 FORM 4 SUBMISSION 0000899243-21-000700 5388
2020-11-25 4 FORM 4 SUBMISSION 0000899243-20-032155 5778
2020-11-19 8-K 8-K 1.01 0001193125-20-297603 001-38327 201327131 34 145227 1 1
2020-11-09 10-Q 10-Q Q3 2020 0001564590-20-052490 001-38327 201297708 34 7324872 1 1
2020-10-06 4 FORM 4 SUBMISSION 0000899243-20-027608 8784
2020-10-01 4 FORM 4 SUBMISSION 0000899243-20-026662 6577
2020-09-18 4 FORM 4 SUBMISSION 0001209191-20-051145 5177
2020-09-18 3 FORM 3 SUBMISSION 0001209191-20-051142 6793
2020-09-17 8-K 8-K 5.02 0001193125-20-247622 001-38327 201180129 34 145000 1 1
2020-08-25 4 FORM 4 SUBMISSION 0001209191-20-048212 13261
2020-08-24 8-K 8-K 1.01,5.02,9.01 0001193125-20-228378 001-38327 201128108 34 246656 1 1
2020-08-10 4/A FORM 4/A SUBMISSION 0001209191-20-045921 9625
2020-08-07 10-Q 10-Q Q2 2020 CUE 0001564590-20-038375 001-38327 201085726 34 7232856 1 1
2020-08-07 4 FORM 4 SUBMISSION 0001209191-20-045702 9162
2020-08-07 4 FORM 4 SUBMISSION 0001209191-20-045698 8624
2020-08-05 4 FORM 4 SUBMISSION 0001209191-20-045144 14939
2020-08-05 4 FORM 4 SUBMISSION 0001209191-20-045142 18254
2020-07-15 8-K 8-K 5.03,5.07,9.01 0001193125-20-193348 001-38327 201029525 34 33455
2020-06-26 8-K 8-K 1.01,9.01 0001193125-20-180915 001-38327 20994174 34 27786
2020-06-25 4 FORM 4 SUBMISSION 0001209191-20-038885 7864
2020-06-22 8-K 8-K 1.01,9.01 0001193125-20-175747 001-38327 20979688 34 197868
2020-06-22 424B5 424B5 0001193125-20-175737 333-239357 20979650 33 655804
2020-06-22 S-3ASR S-3ASR 0001193125-20-175657 333-239357 20979350 33 770166
2020-06-05 8-K 8-K 7.01,9.01 0001193125-20-162176 001-38327 20946152 34 8672168
2020-05-29 DEFA14A DEFA14A 0001193125-20-155724 001-38327 20927815 34 234243
2020-05-29 DEF 14A DEF 14A 0001193125-20-155706 001-38327 20927694 34 562158
2020-05-19 8-K 8-K 2.02,9.01 0001193125-20-146121 001-38327 20893654 34 55603
2020-05-15 PRE 14A PRE 14A 0001193125-20-143998 001-38327 20885592 34 561737
2020-05-12 4 FORM 4 SUBMISSION 0001209191-20-028490 5306
2020-05-07 10-Q CUE-Q1-2020 0001564590-20-022851 001-38327 20856445 34 5079311 1
2020-04-29 10-K/A 10-K/A 0001193125-20-126402 001-38327 20831215 34 243333
2020-04-21 SC 13D/A formsc13da.htm 0001493152-20-006833 005-90232 20805004 34 52414
2020-04-10 4 FORM 4 SUBMISSION 0001209191-20-024164 10821
2020-03-27 8-K 8-K 1.01,9.01 0001193125-20-088890 001-38327 20752554 34 201238
2020-03-27 424B5 424B5 0001193125-20-088881 333-229140 20752516 33 712925
2020-03-26 4 FORM 4 SUBMISSION 0001209191-20-021239 5345
2020-03-17 8-K 8-K 2.02,9.01 0001193125-20-076018 001-38327 20721291 34 73694
2020-03-12 S-8 S-8 0001193125-20-071746 333-237140 20709871 33 58281
2020-03-12 10-K/A 10-K/A 0001193125-20-071718 001-38327 20709775 34 454334
2020-03-12 10-K 10-K 0001564590-20-010212 001-38327 20706956 34 8294237 1
2020-03-02 8-K 8-K 7.01,9.01 0001193125-20-058942 001-38327 20677151 34 9616596
2020-02-24 4/A FORM 4/A SUBMISSION 0001209191-20-012027 7173
2020-02-14 SC 13G SC 13G 0001104659-20-021215 005-90232 20616684 34 49355
2020-02-14 SC 13G CUE BIOPHARMA, INC. 0000902664-20-001125 005-90232 20615222 34 63508
2020-02-12 4 FORM 4 SUBMISSION 0001209191-20-008815 5325
2020-02-12 4 FORM 4 SUBMISSION 0001209191-20-008809 5330
2020-02-12 4 FORM 4 SUBMISSION 0001209191-20-008800 5319
2020-02-12 4 FORM 4 SUBMISSION 0001209191-20-008793 7777
2020-02-10 8-K 8-K 1.01,5.02,9.01 0001193125-20-029740 001-38327 20591848 34 96334
2020-02-07 SC 13G us22978p1066_020620.txt 0000834237-20-008154 005-90232 20584800 34 13123
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002066 5336
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002064 5310
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002063 5347
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002061 5324
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002060 5334
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002058 5287
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002057 5215
2020-01-06 4 FORM 4 SUBMISSION 0001209191-20-002054 5348
2019-12-31 4 FORM 4 SUBMISSION 0001209191-19-062325 9602
2019-12-27 4 FORM 4 SUBMISSION 0001209191-19-062031 8127
2019-12-19 4 FORM 4 SUBMISSION 0001209191-19-061377 12101
2019-12-18 SC 13D formsc-13d.htm 0001493152-19-019389 005-90232 191290859 34 67214
2019-11-26 8-K 8-K 1.01,1.02,9.01 0001193125-19-300091 001-38327 191247310 34 204512
2019-11-25 424B5 424B5 0001193125-19-300046 333-229140 191247121 33 672784

Latest XBRL company facts

One latest value per concept from companyfacts (277 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 8.36M 2026-11-13 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
dei EntityPublicFloat Entity Public Float USD 52.00M 2025-06-30 2025 FY 10-K 2026-03-16 0001193125-26-108287
ffd NetFeeAmt NetFeeAmt USD 5,466.2 2026-08-11 S-3 2026-08-12 0001193125-26-346867
ffd TtlFeeAmt TtlFeeAmt USD 5,466.2 2026-08-11 S-3 2026-08-12 0001193125-26-346867
ffd TtlOfferingAmt TtlOfferingAmt USD 39.58M 2026-08-11 S-3 2026-08-12 0001193125-26-346867
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-11 S-3 2026-08-12 0001193125-26-346867
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-08-11 S-3 2026-08-12 0001193125-26-346867
us-gaap AccountsPayableAndAccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Current USD 1.17M 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap AccountsPayableAndOtherAccruedLiabilities Accounts Payable and Other Accrued Liabilities USD 200,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 3.61M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 5.13M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 1.76M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 15.19M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccruedPayrollTaxesCurrentAndNoncurrent Accrued Payroll Taxes USD 12.14M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.25M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 3.68M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 1,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 615.12M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 59.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 8.40M 2017-01-01 2018-12-31 2020 Q2 10-Q 2020-08-07 0001564590-20-038375
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 1,000 2017-01-01 2018-12-31 2020 Q2 10-Q 2020-08-07 0001564590-20-038375
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 59.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 11,666 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-09 0001564590-21-011777
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 4.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap Assets Assets USD 67.25M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AssetsCurrent Assets, Current USD 66.71M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 57.40M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 1,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 96,000 2022-12-31 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 6.97M 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 6.97M 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 140.65M 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022851
us-gaap Cash Cash USD 20.80M 2018-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 57.94M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 26.60M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -10.43M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 64.40M 2021-12-31 2021 FY 10-K 2022-03-16 0000950170-22-003969
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 16.04M 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029316
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 58.09M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 30.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CertificatesOfDepositAtCarryingValue Certificates of Deposit, at Carrying Value USD 50,000 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 2.7 2015-06-15 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 551,724 2026-04-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 10.72M 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 5.62M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 7.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 7.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap CommonStockValue Common Stock, Value, Issued USD 8,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -208.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 3.00M 2021-11-23 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 5.00M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD -37,000 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap DebtSecuritiesTradingAndAvailableForSale Debt Securities, Trading and Available-for-sale USD 6.97M 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap DeferredFinanceCostsCurrentGross Debt Issuance Costs, Gross, Current USD 9,000 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 142,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap DeferredRentCredit Deferred Rent Credit USD 9,000 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 381,465 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 4,000 2017-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 96.82M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 19.76M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 933,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 60.65M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 988,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 5.06M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 1.11M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 95.89M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap DepositAssets Deposit Assets USD 777,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029316
us-gaap DepositsAssetsCurrent Deposits Assets, Current USD 47,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap DepositsAssetsNoncurrent Deposits Assets, Noncurrent USD 84,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap Depreciation Depreciation USD 137,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 635,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax USD 26.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -28.7 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.81 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0000950170-22-014747
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -28.7 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.019 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.201 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0000950170-22-003969
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.019 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.05 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0.02 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.032 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 1.10M 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-224091
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 9.13M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap FinanceLeaseInterestExpense Finance Lease, Interest Expense USD 200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 10,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 120,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 80.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -53.01M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 5.26M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -5.48M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 1.13M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -65,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 845,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -340,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD -390,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -414,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IncreaseDecreaseInAccruedInterestReceivableNet Increase (Decrease) in Accrued Interest Receivable, Net USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 16.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IncreaseDecreaseInDeposits Increase (Decrease) in Deposits USD -551,000 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-08 0001564590-19-030813
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 184,000 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-12 0000950170-25-107270
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 870,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IndefiniteLivedTrademarks Indefinite-Lived Trademarks USD 175,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029316
us-gaap InterestExpense Interest Expense USD 98,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap InterestExpenseOther Interest Expense, Other USD 200,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD -11,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 819,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 20.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap LandSubjectToGroundLeases Land Subject to Ground Leases sqft 13,000 2022-03-28 2022 Q1 10-Q 2022-05-10 0000950170-22-008990
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 3.37M 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 921,000 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 559,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 553,000 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.89M 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 1.17M 2020-09-30 2020 Q3 10-Q 2020-11-09 0001564590-20-052490
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 291,000 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap Liabilities Liabilities USD 28.86M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 67.25M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap LiabilitiesCurrent Liabilities, Current USD 19.73M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap LongTermDebt Long-term Debt USD 1.00M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 4.00M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 1.00M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 4.00M 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 4.00M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127005
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 0 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap LossOnSaleOfInvestments Loss on Sale of Investments USD 612 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap MarketableSecurities Marketable Securities USD 27.10M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 80.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -121,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -673,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -50.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -9.76M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-14 0001564590-18-013461
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -208.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap NetInvestmentInLeaseAllowanceForCreditLossWriteoff Net Investment in Lease, Allowance for Credit Loss, Writeoff USD 498,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -68.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingExpenses Operating Expenses USD 153.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -140.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.57M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap OperatingLeaseLeaseIncome Operating Lease, Lease Income USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 3.08M 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352128
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingLeasePayments Operating Lease, Payments USD 2.06M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 883,839 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 10.80B 2018-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 822,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 818,000 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.80M 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 2.86M 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.37M 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 904,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029316
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 3.31M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-14 0000950170-22-024991
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.098 2025-12-31 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 79,188 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 85,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax USD 1,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 259,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022851
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -10,958 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap OtherLoansPayable Other Loans Payable USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherLoansPayableCurrent Other Loans Payable, Current USD 929,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherLoansPayableLongTerm Other Loans Payable, Long-term, Noncurrent USD 190,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap OtherLongTermDebt Other Long-term Debt USD 36,972 2022-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap OtherLongTermDebtCurrent Other Long-term Debt, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap OtherNoncashExpense Other Noncash Expense USD 30,000 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-10 0001564590-21-026048
us-gaap OtherNoncashIncome Other Noncash Income USD 68,000 2019-01-01 2019-09-30 2020 Q3 10-Q 2020-11-09 0001564590-20-052490
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0000950170-22-003969
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -74,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-09 0001564590-20-052490
us-gaap OtherResearchAndDevelopmentExpense Other Research and Development Expense USD 35.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap OtherShortTermBorrowings Other Short-term Borrowings USD 100,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 4.16M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0000950170-22-003969
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 175,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 121,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 66.16M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-14 0001564590-19-007832
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 77.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 49.00M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 55 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0000950170-22-003969
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 1.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 1.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -208.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PropertyPlantAndEquipmentDisposals Property, Plant and Equipment, Disposals USD 0 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-07 0001564590-20-038375
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 3.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 225,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap RepaymentsOfDebt Repayments of Debt USD 100,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069125
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 72.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap RestrictedCash Restricted Cash USD 150,000 2020-09-30 2020 Q3 10-Q 2020-11-09 0001564590-20-052490
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 50,068 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010212
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 154,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap RestrictedStockAwardForfeitures Restricted Stock Award, Forfeitures USD 200,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -576.73M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 13.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount USD 2.50M 2022-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 1.12M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap SecurityDepositLiability Security Deposit Liability USD 595,000 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019646
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 59.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 10.1 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-224091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 52,500 2021-08-20 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 14.98 2021-08-20 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.056 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.886 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.049 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.039 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 0 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-224091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 404,587 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 108.21 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 27,225 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 120,380 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 4.90M 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value USD/shares 0.82 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277466
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 1.71M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 48.76 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 217,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022851
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period shares 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058838
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 21.8 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 230.78 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 28.15 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 29.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ShortTermBorrowings Short-term Debt USD 100,000 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069125
us-gaap StockGrantedDuringPeriodValueSharebasedCompensation Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture USD 0 2022-04-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0000950170-22-014747
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 38.40M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 7.66M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 62,818 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 13.39M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 10.81M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047677
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Stock Issued During Period, Value, Restricted Stock Award, Forfeitures USD 55 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-21 0000950170-23-008927
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 0 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 1.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments USD 96,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038059
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 3.40M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 19,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 281,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-108287
us-gaap ValueAddedTaxReceivableCurrent Value Added Tax Receivable, Current USD 1.90M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap ValueAddedTaxReceivableNoncurrent Value Added Tax Receivable, Noncurrent USD 1.90M 2025-06-30 2025 Q2 10-Q 2025-08-12 0000950170-25-107270
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 7.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 34.01M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0000950170-22-014747
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 7.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463755

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →